Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

4.010 +0.040 (+1.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 32,316
Open 3.930
Bid (Size) 3.950 (2)
Ask (Size) 4.120 (1)
Prev. Close 3.970
Today's Range 3.850 - 4.090
52wk Range 2.550 - 6.118
Shares Outstanding 10,799,417
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT
From Lantern Pharma Inc.
Via Business Wire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress
Via Investor Brand Network
Topics Artificial Intelligence

Performance

YTD
+21.5%
+21.5%
1 Month
-7.8%
-7.8%
3 Month
-9.7%
-9.7%
6 Month
+10.8%
+10.8%
1 Year
+23.0%
+23.0%

More News

Read More
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.
From Lantern Pharma Inc.
Via Business Wire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 30
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Advancing Drug Discovery with PredictBBB.ai(TM) Partnership
Via Investor Brand Network
Topics Artificial Intelligence
MissionIRNewsBreaks – RADR(R) Platform Powers Lantern Pharma Inc.’s (NASDAQ: LTRN) Push Into Rare Pediatric Brain Cancer Treatment
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Inc. (NASDAQ: LTRN) CEO Panna Sharma and New Board Member Dr. Lee Schalop Discuss How AI Can Reshape CNS Oncology Drug Development
Via Investor Brand Network
Topics Artificial Intelligence
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-powered PredictBBB.ai Platform Helps Hoth Therapeutics Streamline Candidate Selection in Drug Development
Via Investor Brand Network
Topics Artificial Intelligence
Wondering what's happening in today's after-hours session?
Via Chartmill
FDA Guidance Sets Lantern Pharma Inc. (NASDAQ: LTRN) On a Path Toward Realizing Its Clinical Trial Plans for Rare Pediatric Cancer Therapy
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Aligns With Industry Call to Fix “Broken” Biotech Model
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Achieves Key Milestone in Global Trial for Never-Smoker Lung Cancer
Via Investor Brand Network
Topics Artificial Intelligence
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Completes Phase 1a Trial of LP-184 With Favorable Safety, PK Profile and Early Antitumor Activity
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Completes FDA Type C Meeting, Gains Guidance for Planned Pediatric CNS Cancer Trial
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial
From Lantern Pharma Inc.
Via Business Wire
MissionIRNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Advances Predictive Power in Cancer Drug Development
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Inc. (NASDAQ: LTRN) Reports Q2 Results with Clinical Trial, AI Platform Advancements
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Lantern Pharma Inc. (NASDAQ: LTRN) Releases Latest AI Breakthrough for Central Nervous System (‘CNS’) Drug Development with predictBBB.ai (TM): A High-Accuracy Open-Access AI Drug Development Tool
Via Investor Brand Network
Topics Artificial Intelligence
RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26
Via ACCESS Newswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses in Multiple Trials, Expands AI Platform
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property

Frequently Asked Questions

Is Lantern Pharma Inc. - Common Stock publicly traded?
Yes, Lantern Pharma Inc. - Common Stock is publicly traded.
What exchange does Lantern Pharma Inc. - Common Stock trade on?
Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lantern Pharma Inc. - Common Stock?
The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market
What is the current price of Lantern Pharma Inc. - Common Stock?
The current price of Lantern Pharma Inc. - Common Stock is 4.010
When was Lantern Pharma Inc. - Common Stock last traded?
The last trade of Lantern Pharma Inc. - Common Stock was at 10/31/25 04:00 PM ET
What is the market capitalization of Lantern Pharma Inc. - Common Stock?
The market capitalization of Lantern Pharma Inc. - Common Stock is 43.31M
How many shares of Lantern Pharma Inc. - Common Stock are outstanding?
Lantern Pharma Inc. - Common Stock has 43M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.